<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Abdul-Ghani, Muhammad</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Metformin/Pioglitazone/Exenatide Triple Therapy Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed Type 2 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results of the Durability of Combination Therapy With Exenatide/Metformin Versus Conventional Therapy in New Onset T2DM study [NCT01107717] that evaluated the effects of a triple-therapy regimen versus stepwise add-on conventional therapy in patients with newly diagnosed type 2 diabetes. In this open-label study, 155 patients were randomized to triple therapy or stepwise add-on conventional therapy, with a goal of achieving an HbA1C of &lt;6.5%.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>